314 related articles for article (PubMed ID: 30132271)
1. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Pal SK; Forero-Torres A; Thompson JA; Morris JC; Chhabra S; Hoimes CJ; Vogelzang NJ; Boyd T; Bergerot PG; Adashek JJ; Li H; Yu X; Gartner EM; Carret AS; Smith DC
Cancer; 2019 Apr; 125(7):1124-1132. PubMed ID: 30624766
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
Wu CH; Wang L; Yang CY; Wen KW; Hinds B; Gill R; McCormick F; Moasser M; Pincus L; Ai WZ
Blood Adv; 2022 Apr; 6(7):2290-2302. PubMed ID: 34872108
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Yazbeck V; Shafer D; Perkins EB; Coppola D; Sokol L; Richards KL; Shea T; Ruan J; Parekh S; Strair R; Flowers C; Morgan D; Kmieciak M; Bose P; Kimball A; Badros AZ; Baz R; Lin HY; Zhao X; Reich RR; Tombes MB; Shrader E; Sankala H; Roberts JD; Sullivan D; Grant S; Holkova B
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):569-575.e1. PubMed ID: 30122201
[TBL] [Abstract][Full Text] [Related]
9. A phase I study evaluating ibritumomab tiuxetan (ZevalinĀ®) in combination with bortezomib (VelcadeĀ®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195
[TBL] [Abstract][Full Text] [Related]
12. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S; Winderlich M; Dirnberger-Hertweck M; Korolkiewicz R; Blum KA
Ann Oncol; 2018 May; 29(5):1266-1272. PubMed ID: 29444231
[TBL] [Abstract][Full Text] [Related]
13. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
14. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
Ryan MC; Palanca-Wessels MC; Schimpf B; Gordon KA; Kostner H; Meyer B; Yu C; Van Epps HA; Benjamin D
Blood; 2017 Nov; 130(18):2018-2026. PubMed ID: 28903943
[TBL] [Abstract][Full Text] [Related]
17. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
Witzig TE; Vose JM; Zinzani PL; Reeder CB; Buckstein R; Polikoff JA; Bouabdallah R; Haioun C; Tilly H; Guo P; Pietronigro D; Ervin-Haynes AL; Czuczman MS
Ann Oncol; 2011 Jul; 22(7):1622-1627. PubMed ID: 21228334
[TBL] [Abstract][Full Text] [Related]
18. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
de Vos S; Forero-Torres A; Ansell SM; Kahl B; Cheson BD; Bartlett NL; Furman RR; Winter JN; Kaplan H; Timmerman J; Whiting NC; Drachman JG; Advani R
J Hematol Oncol; 2014 Jun; 7():44. PubMed ID: 24919462
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.
Kaplan LD; Deitcher SR; Silverman JA; Morgan G
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):37-42. PubMed ID: 24252360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]